Since METTL3 up-regulation and ALKBH5 and YTHDF2 down-regulation contribute to the progression of RA, METTL3, ALKBH5, and YTHDF2 may also be targeted for treatment. This evidence concerns the gene METTL3 and rheumatoid arthritis.